ASAP Act
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Overview
This bill, the Alzheimer's Screening and Prevention Act, aims to expand Medicare coverage for blood-based tests used to detect early signs of Alzheimer’s disease and related dementias. Starting January 1, 2028, Medicare will cover tests that meet specific criteria, such as being approved by the Food and Drug Administration and providing comparable results to other diagnostic methods. The bill also adjusts Medicare payment procedures to reflect this new coverage.
Key provisions
- Medicare will cover blood-based tests for early detection of Alzheimer’s disease and related dementias.
- Coverage begins on January 1, 2028.
- Tests must be FDA-cleared or approved.
- The bill defines ‘Alzheimer’s disease and related dementias early detection screening test’.
- The definition includes genomic sequencing tests, blood tests, and other equivalent blood-based tests.
- Medicare payment procedures are adjusted to accommodate the new coverage.
Who is affected
- Medicare beneficiaries
- Individuals at risk for Alzheimer’s disease
- Healthcare providers administering the tests
- Pharmaceutical companies developing and manufacturing the tests
Notable changes
- Expands Medicare coverage to include blood-based dementia screening tests.
- Establishes a specific timeline (January 1, 2028) for coverage implementation.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
49 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours